Deena Beasley

3 days ago | kfgo.com | Deena Beasley |Leslie Adler

By Deena Beasley(Reuters) -Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck’s immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer.

3 days ago | today.westlaw.com | Deena Beasley

(Reuters) -Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer.

6 days ago | watoday.com.au | Deena Beasley |Manas Mishra

Exponential Interactive, Inc d/b/a VDX.tvCookie duration: 90 (days). Data collected and processed: IP addresses, Device identifiers, Probabilistic identifiers, Browsing and interaction data, Non-precise location data, Users’ profiles, Privacy choicesmoreCookie duration resets each session. View details | Privacy policyConsentCookie duration: 365 (days).

6 days ago | smh.com.au | Deena Beasley |Manas Mishra

By Deena Beasley and Manas Mishra April 18, 2025 — 8.43am, register or subscribe to save articles for later. Add articles to your saved list and come back to them any time. Eli Lilly said its experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, with the company expecting to seek global regulatory approvals this year.

6 days ago | marketscreener.com | Deena Beasley |Manas Mishra

(Reuters) -Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year. Shares jumped 16% as results of the study, the first of several underway on the pill, orforglipron, raised hopes of an effective and easy-to-use treatment reaching a market dominated by weight-loss injections.